Aromatase inhibitors and TAM in the treatment of post-menopausal Luminal B breast cancer patients
10.3760/cma.j.issn.1007-631X.2010.06.007
- VernacularTitle:绝经后Luminal B型乳腺癌的内分泌治疗
- Author:
Jinghong ZHANG
;
Yan LIU
;
Xiaomeng HAO
;
Rui HUI
;
Fenglin ZANG
;
Peng LIU
;
Yuanxi ZHU
;
Yi YANG
;
Jin ZHANG
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Genes,erbB-2;
Aromatase inhihitom;
TAM;
Endocrine therapy
- From:
Chinese Journal of General Surgery
2010;25(6):449-452
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate a therapeutic strategy using aromatase inhibitors and TAM in postmenopausal Luminal B breast cancer patients. Methods The clinical data of 733 primary breast cancer cases receiving postoperative endocrine thempy from July 2002 to Mar 2005 in Tianjin Cancer Hospital were retrospectively analyzed.Diagnosis was confirmed by pathology in all the cases.All patients were post-menopausal and ER-positive.501 patients were given tamoxifen(TAM 2.5 mg qd,po),232 patients were given aromatase inhibitors(Letrozole 10 mg bid,po).The follow-up time ranged from 36 to 90 months.Median follow-up time was 46 months.Results The disease-free-survival(DFS)rate of Luminal B breast cancer patients in aromatase inhibitors(AIS)group was higherthan that in TAM group(90.6% vs.88.6%,P=0.038).In TAM group,subgroup analysis showed 3-year DFS of node-positive with HER2(+)is lower than that of node-positive with Her-2-negative(88.2% vs.90.4%,P=0.037);3-year DFS of ER+/PR+ group in HER2(+) patients was higher than that of ER+/PR-group(90.8% vs.89.5%.P=0.032).In AIs group,in spite of the axillary lymph node status,there was no significant difference of 3-year DFS between HER2(+)patients and HER2(-)ones(P>0.05).3-year DFS of ER+/PR+with HER2(+) patients was higher than that of ER+/PR-ones with HER2(+)(91.9% vs.90.5%,P=0.029).Hot flush,vaginal bleeding and thromboembolics in AIS group is less frequent,but muscle pain and bone fracture is more common than that in TAM group(P<0.05).Conclusion Compared to TAM, AIs is more effective and safer with postmenopausal Luminal B patients,and the effect is independent on node stams.
